Journal of Pathology, Microbiology, and Immunology welcomes Mark TS Williams as new associate editor.
Mark Thomas Shaw Williams graduated with a BSc (Hons) in Immunology and Pharmacology from the University of Strathclyde in 2006, before undertaking a PhD investigating inflammation in cystic fibrosis at Queen’s University Belfast with Professor Madeleine Ennis and Professor Stuart Elborn in 2007.
Subsequently, he worked as a Research Associate at the Institute of Infection, Immunity and Inflammation (3Is) at the Glasgow Biomedical Research Centre, University of Glasgow from 2010 to 2016. It is here where Mark conducted novel studies into Acute Lymphoblastic Leukaemia and Multiple Myeloma with Professor Christina Halsey, Professor Gerry Graham and Professor Carl Goodyear.
Mark was appointed as Lecturer in Cancer Biology within the Department of Biological and Biomedical Sciences, and the research sub-group Molecular Mechanisms and Therapeutics in 2017.
More than 14 years of expertise
Mark has over 14 years of expertise in researching blood cancers, including Acute Myeloid Leukaemia (AML) and Myeloma (MM), and has identified new therapeutically targetable disease mechanisms. His Research Group is focusing on identifying and targeting bone marrow microenvironment (BME) driven therapy resistance mechanisms in AML and MM.
In close collaboration with national and international researchers his group is also developing and investigating novel antibody-based therapeutics and protein degraders/PROTACs in Myeloma and AML. Ongoing studies in the Williams Research Group are focussing on the contribution of macrophages and fibroblasts towards BME-mediated therapy resistance, as well as investigating the mechanisms by which AML and MM cells reprogram cellular elements of the BME in AML and MM.
Springboard Award from the Academy of Medical Science
In February 2022 Mark was awarded a Springboard Award from the Academy of Medical Sciences to further develop his Research Group. Mark is a member of the Royal Academy of Edinburgh Young Academy of Scotland, and also holds affiliate status at the School of Cancer Sciences, University of Glasgow.
We look forward to working together!
